Business Wire

PKU: APR Applied Pharma Research Presents New Data from a Global Research at the 40th SIMD Annual Meeting

Jaa

APR Applied Pharma Research s.a. (“APR”), the Swiss independent developer of science driven and patent protected healthcare products, participates in the 40th edition of the annual meeting promoted by SIMD (Society for Inherited Metabolic Diseases), which is held on March 11 th -14 th , in San Diego, California. Within the congress, APR presents the results of a global market research project on PKU (Phenylketonuria), a rare, genetic, recessive metabolic disorder. This qualitative research has been conducted by IDR Medical, a leading international healthcare market research organization, in the United States and five European Countries (France, Germany, Spain/Portugal, Italy, UK) in order to evaluate how PKU is currently managed, with the aim of identifying areas for improvement. A total of 96 interviews with pediatricians, dieticians and PKU care-givers or patients provided insights to unfold many aspects of PKU management, including patient flows, stakeholders’ influence and decision criteria for medical food adoption.

The final results and conclusions of the survey indicate that patients’ adherence to the currently prescribed amino acid (AA) supplements is still a key issue and that it is mainly driven by taste fatigue. Dieticians and pediatricians have still to make great efforts to reach a good long-term patient compliance to the recommended dietary regimen, which is pivotal to achieve the desired balance between adequate nutritional intake and good metabolic control with PHE levels within the ranges. These difficulties are also confirmed by patients, who highlighted how the most highly ranked aspects in terms of importance in the choice of an AA supplement are taste, good control of phenylalanine (Phe) levels and the contribution to personal wellbeing.

The research supports the relevance of an innovative supplementation addressing some of these needs and thus significantly contributing to ameliorate PKU management.

APR developed a patented new technology (known as Physiomimic Technology TM ), with the precise objective of providing PKU patients with an innovative Phe-free AA supplement, which can concomitantly help patients remain adherent to the prescription of amino acid supplementation as well as improve their quality of life.
In particular, the technology is able to remarkably mask the naturally unpleasant taste and the odor of some amino acids, offering a considerably palatable medical food, which can be easily accepted by patients, helping them to obtain a rewarding and lasting compliance to the dietary treatment, positively impacting their quality of life.

On the other side, the supplementation, by providing amino acids in a physiological manner, has the very encouraging potential of increasing the rate of amino acid assimilation into protein and balancing the steep blood fluctuations typical of the free amino acids, aspects that are being studied for their expected benefits on patients’ health.

“We are very pleased of the results of this extensive research, now validated by the poster “Phenylketonuria: not all problems are solved”, as they confirm product palatability as one of the main open issues in the management of PKU, resulting in poor long-term compliance. - states Paolo Galfetti, CEO of Applied Pharma Research-. We are confident that APR’s innovative Medical Food will deliver tangible and significant benefits to PKU patients, by making easier to accept life-long daily dietary restrictions and thus contributing to their wellbeing.”

Further results and advancements will be presented by APR at the 56 th Annual Symposium of the SSIEM (Society for the Study of Inborn Errors of Metabolism) on September 4 th -7 th in Athens, which will be a great occasion for clinicians to get to know APR innovation and the patented technology behind it.

About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected Healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies, in over 70 countries with international sales on a worldwide basis.

About Phenylketonuria or PKU
Phenylketonuria or PKU is a rare, genetic, recessive metabolic disorder affecting about 50.000 people worldwide. PKU is characterized by the deficiency or the malfunctioning of a liver enzyme needed to process phenylalanine (“Phe”), an essential amino acid found in most protein-containing food. Excessive amounts of Phe in the bloodstream become toxic to the brain, impairing the normal development of the central nervous system. If not properly treated, PKU leads to severe, non-recoverable mental retardation and major cognitive disabilities. PKU can only be treated through a strict, life-long, low-protein (low-Phe) dietetic treatment combined with a daily assumption of low-protein modified foods and medical food, which provides Phe-free amino acids and other important nutrients, needed due to the dietary restrictions of PKU patients.

For more information about Physiomimic™ Technology, please visit: www.apr.ch/apr-pharma-products/medical-prescription/genetic-metabolic-disease/
For press releases and other company information visit: www.apr.ch

Contact information

APR Applied Pharma Research s.a.,
Paolo Galfetti; CEO
T: +41 91 6957020 or email to paolo.galfetti@apr.ch
or
Havas PR Milan - Press Office
Sara Bernabovi
T: +39 02 85457032 or email to sara.bernabovi@havaspr.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

NEC and Samsung Announce 5G Partnership Agreement24.10.2018 04:00Tiedote

NEC Corporation (NEC) (TOKYO: 6701) and Samsung Electronics Co., Ltd., today announced a partnership of joint effort to strengthen their next generation business portfolio including 5G. The partnership brings together the best-in-class technology and expertise in 5G, merging NEC and Samsung’s leadership in 5G and IT solutions. It also provides mobile carriers with flexible 5G solutions that are localized for each region with customized services to meet mobile carriers’ demands efficiently. Since 5G will enable unprecedented services and business models, it is inevitable for mobile carriers to demand customized solutions and flexible network architecture. Through this partnership, both companies will satisfy these growing demands effectively by joining the best forces and capabilities from each company. "5G development based on standardization will help to accelerate business transformation throughout global markets,” said Atsuo Kawamura, Executive Vice President and President of the Ne

Coronation Fund Managers Goes Live with SmartStream’s Corporate Actions Solution24.10.2018 02:01Tiedote

SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced that Coronation Fund Managers, one of the largest independent fund managers in South Africa, has gone live with TLM Corporate Actions OnDemand – automating the complete corporate actions lifecycle. Llewellyn Smith, COO at Coronation states: “We continue to make investments in our business, specifically in technology that enhances our clients’ service experience, and which allows us to achieve greater operational efficiencies. Through SmartStream’s tailored solution, we achieve automation of our corporate actions operational processes. Given that this project ran in parallel with a number of strategic initiatives, its successful implementation was essential. We value SmartStream’s corporate actions expertise which guided us through the procedure in less than four months”. Coronation is using the TLM® Corporate Actions OnDemand solution to process mandatory and voluntary ev

EASA Approves AerTrak ADS-B Out System for Boeing 737 NG Series Aircraft24.10.2018 00:47Tiedote

AerSale ®, a global supplier of mid-life aircraft, engines, used serviceable material, and MRO services, announced today that the European Aviation Safety Agency (EASA) has approved the company’s AerTrak™ ADS-B Out system on Boeing 737 NG series aircraft (10065422). Earlier this year, the Federal Aviation Administration (FAA) approved AerTrak for Boeing 737 NG series aircraft (ST04009NY) and Boeing 757-200 series aircraft (ST04011NY) to comply with the FAA’s Automatic Dependent Surveillance-Broadcast (ADS-B) Operations rule. The Boeing 757-200 series aircraft Supplemental Type Certificate (STC) is now pending EASA and National Civil Aviation Agency of Brazil (ANAC) validation. “With this validation, we demonstrate our commitment to our European customer base,” said Iso Nezaj, Chief Technical Officer at AerSale. “Operators can now choose a fully-compliant ADS-B Out system visible to all—with no certification fees. We’re working to expand AerTrak to cover additional aircraft types and lo

Greene Tweed Receives Patent for Rapid Gas Decompression-Resistant Fluoroelastomers and Molded Articles24.10.2018 00:00Tiedote

The U.S. Patent Office has awarded Greene Tweed Patent Number 10,011,690 for Rapid Gas Decompression-Resistant Fluoroelastomer Compositions and Molded Articles. The innovative elastomer technology was developed by a team that included inventor Ron Campbell, PhD, Principal Scientist and Technology Leader for Elastomers in Greene Tweed’s Advanced Technology Group, to provide a competitive advantage in the Energy market and expand technology protected under a previous patent. Rapid gas decompression (RGD) often occurs when high-pressure gas molecules migrate into an elastomer at a compressed state. When the pressure surrounding the elastomer is suddenly released, the compressed gas inside the elastomer tries to expand and exit the elastomer, thus causing RGD (also known as explosive decompression). Most elastomers experience severe blistering or cracking when the force of these expanding gases overcome the strength of the surrounding material; however, materials engineered to withstand RG

Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains23.10.2018 21:00Tiedote

Scientists at Morinaga Milk Industry Co., Ltd. (TOKYO:2264) have long theorized that Human-Residential Bifidobacteria (HRB) are superior to non-Human-Residential Bifidobacteria (non-HRB) in promoting good health outcomes. The results of a new study strengthen the evidence for this theory, showing that infant-type HRB may be able to break down incompletely digested peptides in the infants’ gastrointestinal systems and thus contribute to their overall health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005015/en/ Fig 1. Food-derived opioid peptides are potential risk factors for human health (Graphic: Business Wire) Human-Residential Bifidobacteria for Humans Morinaga Milk has been conducting research on bifidobacteria for many years, and studies over the past decades have shown that bifidobacteria play a vital role in various aspects of human health. There are two major groups of bifidobacteria: Human-Residential Bif

myPOS Founder Christo Georgiev Announces Two Upcoming myPOS Stores in Barcelona and Paris23.10.2018 19:22Tiedote

Christo Georgiev, fintech entrepreneur and founder of myPOS, has confirmed his intention to open two new flagship stores in major European cities by the end of the year. The opening is part of an initiative to bring the product closer to potential customers, giving them a hands-on experience and a live demonstration of what myPOS has to offer. The two new stores will be opened in Barcelona, Spain and Paris, France – two of the most important markets for myPOS. “Our Spanish and French customers have always placed a tremendous amount of trust in us, and we in turn have worked hard to justify it,” Georgiev says. “Opening physical locations in Barcelona and Paris is an extension of that relationship. It’s important to test a product with your own hands before you choose to trust it, and if that’s true for TVs and phones why can’t it apply to POS terminals?” The Barcelona store will open as soon as November, followed shortly by the Paris one before the end of the year. myPOS has already ope

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme